Introduction {#ss1}
============

Sensorineural hearing loss (SNHL) is one of the most common birth defects. Genetic causes of SNHL can be found in half of prelingual cases and the remaining half are ascribed to environmental or unidentified genetic factors. The most common environmental cause of SNHL is congenital cytomegalovirus (CMV) infection, with an estimated overall birth prevalence of approximately 0.3--2.4% \[[@CIT0001]\]. The vast majority (approximately 90%) of these infants exhibit no signs of congenital infection, which is asymptomatic at birth. Approximately 10% of infected infants are born with clinical symptoms of congenital CMV infection. SNHL reportedly occurs in 22--65% of children with symptomatic congenital CMV infections and 6--23% of children with asymptomatic infections \[[@CIT0002]\].

Late-onset and progressive natures are characteristic of SNHL with congenital CMV infection. The frequency of SNHL in children with asymptomatic congenital CMV infection is also uncertain. The gold standard for diagnosis of congenital CMV infection is the isolation of the virus from urine or saliva in the first 2 weeks of life. However, asymptomatic congenital CMV infection in children who develop late-onset SNHL after 2 weeks of age cannot be diagnosed on the basis of viral isolation from urine or saliva. Detection of CMV DNA in infant blood or umbilical cord using polymerase chain reaction (PCR) assays is a more feasible method to identify children with late-onset of SNHL. Blood stored as dried blood spots (DBS) on Guthrie cards and the dried umbilical cord that is generally stored at home as a memento of the birth in the Japanese culture are suitable for retrospective diagnosis of congenital CMV infection.

Congenital CMV infections and genetic defects are the two major causes of SNHL in children. For severe bilateral SNHL children, Ogawa et al. \[[@CIT0003]\] reported that congenital CMV infection, which was diagnosed by detection of CMV DNA in dried umbilical cord, and genetic defects (*GJB2*) were identified in 15% and 30% of the children, respectively. The etiology of SNHL in children including mild to moderate SNHL and unilateral SNHL is still uncertain. The purpose of the present study was to investigate the prevalence of congenital CMV infection diagnosed retrospectively by detection of CMV DNA extracted from dried umbilical cord specimens in children with unilateral or bilateral SNHL defined at an age of months or even years after birth. Genetic testing was also applied to identify the other causes of SNHL.

Material and methods {#ss2}
====================

Subjects {#ss3}
--------

This study evaluated 134 patients (70 males and 64 females) with bilateral (46 patients) or unilateral (88 patients) SNHL who were referred to the Department of Otolaryngology, Shinshu University School of Medicine, from May 2008 to September 2009 ([Table I](#T1){ref-type="table"}). Informed consent and dried umbilical cord for the preparation of DNA specimens were collected for all of them. The ages of children who were diagnosed with SNHL ranged from 1 month to 138 months (mean age 37.7 ± 36.2 months). Children with deafness syndrome were excluded from this study by an etiologic work-up of their SNHL. Both genetic deafness testing and CMV DNA analysis were performed for children with bilateral SNHL. For children with unilateral SNHL, CMV DNA analysis and genetic test (*GJB2, Mit1555*) were performed.

###### 

Summary of children with bilateral and unilateral hearing loss.

  Hearing loss            Gender (*n*)     Hearing level (dB)   Affected side (*n*)   Severe to profound hearing loss   Mild to moderate hearing loss                
  ----------------------- ---------------- -------------------- --------------------- --------------------------------- ------------------------------- ------------ -------------
  Total (*n* = 134)       M = 70, F = 64                                              101 (75.4%)                       34.4 ± 34.7                     33 (24.6%)   48.8 ± 38.7
  Bilateral (*n* = 46)    M = 31, F = 15   71.8 (R) 71.7 (L)                          28 (20.9%)                        16.6 ± 19.9                     18 (13.4%)   11.1 ± 39.1
  Unilateral (*n* = 88)   M = 39, F = 49   89.5 (W) 13.6 (B)    R = 43, L = 45        73 (54.5%)                        41.2 ± 36.6                     15 (11.2%)   40.3 ± 36.8

M, male; F, female; R, right; L, left; B, better hearing ear; W, worse hearing ear.

Audiologic evaluations {#ss4}
----------------------

Audiometric evaluation was performed for each patient using auditory brainstem response (ABR) and auditory steady-state evoked response (Master 580-Navpro; Nihon Kohden Co. Ltd, Tokyo, Japan) as objective audiologic tests and behavioral audiologic tests and/or pure tone audiometry were also used. Hearing levels (average of 500, 1000, 2000, 4000 Hz) of the patients were classified into two categories on the basis of the severity of the worse ear: severe (71--90 dB) to profound (\>90 dB), mild (20--40 dB) to moderate (41--70 dB). The threshold of ABR was determined as a means of hearing level in 5 of 134 children with hearing loss. The follow-up hearing assessments were performed at intervals of 6--12 months. Progressive hearing loss was defined as a decrease in hearing of 10 dB or more at one or more frequencies. Fluctuating hearing loss was defined as a decrease in hearing of \>10 dB followed by an improvement of \>10 dB at one or more frequencies.

Preparation of DNA samples and real-time PCR analysis and genetic testing {#ss5}
-------------------------------------------------------------------------

To analyze congenital CMV infection, we used CMV-DNA quantitative PCR (qPCR) analysis. Before qPCR analysis, the total DNA including genomic DNA and CMV DNA was extracted from preserved dried umbilical cords. Preserved dried umbilical cord samples were collected from hearing loss patients and controls. As a positive control, we used preserved umbilical cords from two patients with symptomatic congenital CMV infection, identified by CMV from urine in the first 2 weeks of life at the Department of Pediatrics, Shinshu University Hospital. As a negative control, preserved umbilical cords from five healthy children without SNHL were used. Each 5 mm section of the tissue was incubated in the lysis buffer containing proteinase K and incubated at 56°C overnight. Total DNA was extracted using a DNeasy Blood & Tissue Kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer\'s instructions. The total amount of DNA was measured by Qubit Fluorometer with Quant-iT™ dsDNA BR Assay Kit (Life Technologies-Invitrogen, Carlsbad, CA, USA). Each 10 pg total DNA was analyzed by a Step One Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) using a TaqMan Universal Master Mix II (Applied Biosystems). The qPCR primers and TaqMan probe used for CMV DNA qPCR analysis are listed below: US14-1F, 5\' ACGTCCACGTTAGGATGAGG 3\'; US14-1R, 5\' GTATGTGGCGCTTCTCTCGT 3\'; US14-1 TaqMan probe, 5\'-FAM-AACCTGTGCACCACAGCGCC-TAMRA-3\'. To quantify the input DNA amount in each sample, qPCR with genome region was also performed, using the primers and TaqMan probe listed below. GJB2-2F, 5\' ACGTCCACGTTAGGATGAGG 3\'; GJB2-2, 5\' GTATGTGGCGCTTCTCTCGT 3\'; GJB2-2 TaqMan probe, 5\'-FAM- AACCTGTGCACCACAGCGCC-TAMRA-3\'. Initial preheating steps were performed for 2 min at 50°C and 10 min at 95°C. Then qPCR was performed with 43 cycles of 15 s at 95°C and 60 s at 60°C. After qPCR analysis, relative CMV concentrations of each sample were evaluated as ΔCt (delta threshold cycle), which was calculated by threshold cycle of CMV qPCR minus that of GJB2 qPCR. The invader assay described by Abe et al. \[[@CIT0004]\] was used for deafness genetic testing.

Ethics approval {#ss6}
---------------

This study was approved by the ethical committee of Shinshu University School of Medicine. Written informed consent was obtained from either the patients or their parents.

Results {#ss7}
=======

[Figure 1](#F1){ref-type="fig"} shows original amplification curves of real-time PCR of the positive controls, negative controls, blank controls (samples without added DNA), and results of a typical sample (no. 12) for CMV DNA and genomic DNA (*GJB2* gene). CMV DNA was amplified in two of two cases in positive controls, none of five cases in negative controls, and none of two cases in blank controls (data not shown), therefore we considered this method to be appropriate. Comparing ΔCt for each sample and positive control, CMV DNA content was 0.01--0.8 times for positive control. The present study revealed that 9.0% (12/134) of the cases of children with SNHL were attributable to congenital CMV infection. CMV DNA from preserved umbilical cords was detected in 8.7% of bilateral SNHL cases ([Table II](#T2){ref-type="table"}) and 9.1% of unilateral SNHL cases ([Table III](#T3){ref-type="table"}) in children with SNHL of unknown causes. Bilateral severe to profound SNHL, bilateral mild to moderate SNHL, unilateral severe to profound SNHL, and unilateral mild to moderate SNHL caused by congenital CMV infection were detected in 14.3% (4/28), 0% (0/18), 9.6% (7/73), and 6.7% (1/15) of the hearing-impaired children, respectively.

![An original amplification plot of real-time PCR in case no. 12 with positive CMV DNA. CMV DNA in positive control and case 12 (A) and genomic DNA (GJB2 gene) in positive control, case no. 12 and negative control (B) are amplified. These results show that our real-time PCR method is precise. Blank, sample without any added DNA.](OTO-131-0976-g001){#F1}

###### 

Results of CMV DNA test combined with genetic deafness testing in bilateral sensorineural hearing loss (SNHL).

  Test                    Severe to profound SNHL (*n* = 28)   Mild to moderate SNHL (*n* = 18)   Total (*n* = 46)   
  ----------------------- ------------------------------------ ---------------------------------- ------------------ ------------
  CMV DNA test            Positive                             4 (14.3%)                          0 (0%)             4 (8.7%)
  Deafness gene test      *GJB2*                               6 (21.4%)                          1 (5.6%)           7 (15.2%)
                          *SLC26A4*                            3 (10.7%)                          0 (0%)             3 (6.5%)
                          Other                                0 (0%)                             0 (0%)             0 (0%)
                          Total                                9 (32.1%)                          1 (5.6%)           10 (21.7%)
  Total diagnostic rate                                        46.4%                              5.6%               30.4%

CMV, cytomegalovirus; SNHL, sensorineural hearing loss.

###### 

Results of CMV DNA test combined with genetic deafness test in unilateral sensorineural hearing loss (SNHL).

  Test                    Severe to profound SNHL (*n* = 73)   Mild to moderate SNHL (*n* = 15)   Total (*n* = 88)   
  ----------------------- ------------------------------------ ---------------------------------- ------------------ ----------
  CMV DNA test            Positive                             7 (9.6%)                           1 (6.7%)           8 (9.1%)
  Deafness gene test      *GJB2*                               0 (0%)                             0 (0%)             0 (0%)
                          Other                                0 (0%)                             0 (0%)             0 (0%)
                          Total                                0 (0%)                             0 (0%)             0 (0%)
  Total diagnostic rate                                        9.6%                               6.7%               9.1%

Ten deafness gene mutations (7/10, *GJB2*; 3/10, *SLC26A4*) were identified in 10 (21.7%) of the 46 children with bilateral SNHL. If restricted to the group of children with bilateral severe to profound SNHL, the rates of deafness gene mutations and positive CMV DNA increased to 32.1% (9/28) and 14.3% (4/28), respectively ([Table II](#T2){ref-type="table"}).

[Table IV](#T4){ref-type="table"} shows the clinical characteristics of 12 children in whom CMV DNA was identified. Of them, four children had bilateral SNHL and eight children had unilateral SNHL. All four children with bilateral SNHL had late-onset profound SNHL. The hearing fluctuation and pass at newborn hearing screening (NHS) test were confirmed in three of four children (75%). Among the 2/8 children with unilateral SNHL, pass or failure at NHS test were confirmed in two children, respectively. Only one child (12.5%) had hearing fluctuation. Inner ear anomaly was not found in any of the eight children with unilateral SNHL.

###### 

Clinical data of children positive for CMV DNA.

  Case no.   Sex   Age at diagnosis (months)   Bilateral/unilateral   Affected side   Severity   Average HL (R/L) (dB)   FL/P/NA   Onset         NHS         Delta Ct
  ---------- ----- --------------------------- ---------------------- --------------- ---------- ----------------------- --------- ------------- ----------- ----------
  1          F     60                          Bilateral              R/L             Profound   87.5/108.8              FL/P      Late          Pass        7.52
  2          F     52                          Bilateral              R/L             Profound   87.5/110                FL/P      Late          Pass        8.58
  3          M     50                          Bilateral              R/L             Profound   100.0/100.0             P         Late          Pass        12.94
  4          M     62                          Bilateral              R/L             Profound   110/46.3                −         Likely late   −           0.07
  5          M     6                           Unilateral             L               Profound   32.5/103.8              −         Congenital    Refer (L)   8.01
  6          M     65                          Unilateral             R               Profound   107.5/17.5              −         Unknown       −           11.64
  7          M     50                          Unilateral             L               Profound   6.3/100.0               −         Unknown       −           13.59
  8          F     98                          Unilateral             R               Profound   110/15                  −         Unknown       −           11.67
  9          F     55                          Unilateral             L               Profound   15.0/92.5               −         Late          Pass        8.3
  11         F     2                           Unilateral             R               Profound   90.0/18.3               NA        Congenital    Refer (R)   0.46
  10         M     80                          Unilateral             L               Severe     13.3/70.0               −         Unknown       −           14.32
  12         F     44                          Unilateral             L               Moderate   15.0/58.3               FL/P      Late          Pass        9.41

NHS, Newborn Hearing Screening; FL, fluctuation of hearing loss; P, progressive hearing loss; NA, not applicable.

Discussion {#ss8}
==========

A common method for diagnosis of congenital CMV infection has been detection of CMV DNA from urine within the first 2 weeks of life and serologic testing for CMV-specific IgM antibody in serum from mother and child \[[@CIT0005]\]. In recent years, the detection of CMV DNA by retrospective methods has been more valuable, not only for diagnosing congenital CMV infection during later life, but also for identifying those children who are at highest risk of late-onset and progressive SNHL. There are some reports that DBS stored on Guthrie cards have been used for the retrospective diagnosis of congenital CMV infections \[[@CIT0006],[@CIT0007]\]. Similarly, preserved umbilical cords have been used in Japan recently \[[@CIT0008; @CIT0009; @CIT0010]\]. The sensitivity varies widely depending on the DNA extraction method in the case of DBS. Some investigators reported sensitivities of 71--100% and specificities of 99--100% \[[@CIT0007],[@CIT0011],[@CIT0012]\]. In this study, the qPCR method and preserved umbilical cords were used because they were useful for more precise detection of CMV DNA.

The present study clearly showed that in a certain number of patients, hearing loss (either bilateral or unilateral) is due to CMV infection. Concerning frequencies, positive CMV DNA in children with bilateral SNHL was 8.7% (4/46). Late-onset profound SNHL (4/4: 100%) and hearing progression (3/4: 75%) were characteristic features of SNHL caused by CMV infection.

Hearing loss in children with congenital CMV infection often presents at birth, but in many instances may develop after months or even years \[[@CIT0013]\]. In this study, three-quarters of subjects (75%) passed the NHS. The present results are consistent with the report that children with normal hearing at 6 months of age developed hearing loss at the rate of nearly 1% per year and the cumulative risk of late-onset hearing loss was a substantial 6.9% for the population with asymptomatic congenital CMV infection \[[@CIT0013]\]. Children with bilateral hearing loss have speech developmental problems. Therefore retrospective diagnosis of congenital CMV infection is important to understand more about the etiology of SNHL in children. Previous reports are summarized in [Table V](#T5){ref-type="table"}. The frequency of congenital CMV infection in children with bilateral SNHL varied from 3% to 36%. This large variation may be due to the various backgrounds of the subjects (number of population, severity of SNHL, etc.) or the various methods utilized (e.g. CMV-IgM, DNA from urine, DNA from DBS on Guthrie cards) \[[@CIT0006],[@CIT0012],[@CIT0014; @CIT0015; @CIT0016; @CIT0017; @CIT0018]\]. Meanwhile, based on the retrospective diagnostic method of using preserved dried umbilical cords, congenital CMV infection was detected in 10--12% of children with bilateral SNHL in Japan \[[@CIT0008],[@CIT0009]\], but these reports were based on small numbers of subjects (10--26 cases).

###### 

Review of previous reports.

  Reference                          Year   Subjects                        CMV positive rate   Progression (%)   Late-onset (%)   Study design   Diagnostic methods   Country                          
  ---------------------------------- ------ ------------------------------- ------------------- ----------------- ---------------- -------------- -------------------- --------------- ---------------- -----------------
  Barbi et al. \[[@CIT0012]\]        2003   \>40 dB HL                      9/79 (11.4%)        1/37 (2.7%)       8/42 (19%)       NR             NR                   Retrospective   DBS, qPCR        Italy
  Ogawa et al. \[[@CIT0003]\]        2007   \>20 dB, nonsyndromic SNHL      10/67 (10.5%)       9/63 (14.3%)      1/4 (25%)        NR             NR                   Retrospective   UC, PCR          Japan
  Samileh et al. \[[@CIT0015]\]      2008   \>40 dB HL                      33/95 (34.7%)       NR/75             NR/20            NR             NR                   Prospective     Serologic test   Iran
  Stehel et al. \[[@CIT0016]\]       2008   NHS refer                       16/256 (6%)         16/256 (6%)       NR               NR             NR                   Prospective     DNA from urine   USA
  Walter \[[@CIT0020]\]              2008   Unexplained SNHL                8/35 (22.9%)        NR                NR               NR             NR                   Retrospective   DBS, qPCR        UK
  Mizuno \[[@CIT0021]\]              2008   Only bilateral                  3/45 (6.7%)         3/45 (6.7%)       0                NR             NR                   Prospective     UC, qPCR         Japan
  Jakubikova et al. \[[@CIT0014]\]   2009   \>60 dB HL, NHS refer           4/71 (5.6%)         4/55 (7.3%)       0/16 (0%)        NR             NR                   Prospective     Serologic test   Slovak Republic
  Boudewyns \[[@CIT0022]\]           2009   NHS refer, \>20 dB              4/55 (7.3%)         NR                NR               NR             NR                   Retrospective   DBS, qPCR        Belgium
  Choi \[[@CIT0023]\]                2009   NHS refer                       13/479 (2.7%)       13/479 (2.7%)     NR               NR             NR                   Retrospective   DBS, qPCR        USA
  Tagawa \[[@CIT0024]\]              2009   \>70 dB, deaf schoolchildren    3/26 (11.5%)        3/26 (11.5%)      0 (0%)           2 (7.7%)       1 (3.9%)             Retrospective   UC, qPCR         Japan
  Kimani \[[@CIT0025]\]              2010   NHS refer                       11/109 (10.1%)      8/92 (8.8%)       3/17 (17.6%)     NR             NR                   Retrospective   DBS, qPCR        USA
  Adachi \[[@CIT0026]\]              2010   NHS refer, \>35 dB, bilateral   13/77 (17%)         13/77 (17%)       0                NR             NR                   Retrospective   UC, qPCR         Japan

NR, not reported; DBS, dried blood spot; UC, umbilical cord; qPCR, quantitative PCR.

Genetic deafness testing has become valuable for a precise diagnosis of hearing loss. The most frequent gene implicated in non-syndromic hearing loss is *GJB2*, which is the most prevalent gene responsible for congenital hearing loss worldwide. *GJB2, SLC26A4, CDH23*, and mitochondrial 12s rRNA are the major genetic causes of hearing loss in Japan \[[@CIT0019]\]. Genetic deafness mutations could be detected in 30% of children with congenital hearing loss \[[@CIT0004]\]. In the present study, deafness gene mutations were identified in 21.7% (10/46) of children with bilateral SNHL. In children with bilateral severe to profound SNHL, the frequency of deafness gene mutations and CMV DNA positive results were 32.1% (9/28) and 14.3% (4/28), respectively. The diagnostic rate was concluded to be 46.4% (13/28). If the detection test for CMV DNA could be combined with genetic deafness testing, it would enable us to find approximately 50% of causes of bilateral severe to profound hearing loss in children.

In children with unilateral SNHL, CMV DNA from preserved umbilical cords was detected in 9.1% (8/88). The frequency of congenital CMV infection has been similar in children with unilateral and bilateral SNHL. We have speculated that approximately 10% of SNHL in children is caused by congenital CMV infection. The majority of unilateral SNHL was etiologically unknown, and there were few reports showing the frequency of congenital CMV infection in children with unilateral SNHL. Although 25% (1/4) \[[@CIT0003]\] and 19% (8/42) \[[@CIT0012]\] of children with unilateral SNHL were reported to be diagnosed as having congenital CMV infection by the CMV DNA detection method, the frequency based on a large number of subjects is not available. This is the first report confirming CMV as a very important cause of unilateral SNHL. The present results also showed that CMV is a crucial cause of late-onset unilateral SNHL, and in fact, five of eight subjects passed NHS.

In conclusion, congenital CMV infection plays a major role as a cause of bilateral and unilateral SNHL in children: 9.0% of SNHL of unknown causes (bilateral SNHL, 8.7%; unilateral SNHL, 9.1%) is attributable to congenital CMV infection.

This work was supported by the Acute Profound Deafness Research Committee of the Ministry of Health, Labour and Welfare, Tokyo, Japan, and a grant from the Preventive Medical Center of Shinshu University Hospital.

***Declaration of interest:*** The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.
